R.M. Califf

2.7k total citations · 1 hit paper
27 papers, 1.7k citations indexed

About

R.M. Califf is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Internal Medicine. According to data from OpenAlex, R.M. Califf has authored 27 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Cardiology and Cardiovascular Medicine, 14 papers in Surgery and 7 papers in Internal Medicine. Recurrent topics in R.M. Califf's work include Acute Myocardial Infarction Research (11 papers), Antiplatelet Therapy and Cardiovascular Diseases (8 papers) and Venous Thromboembolism Diagnosis and Management (7 papers). R.M. Califf is often cited by papers focused on Acute Myocardial Infarction Research (11 papers), Antiplatelet Therapy and Cardiovascular Diseases (8 papers) and Venous Thromboembolism Diagnosis and Management (7 papers). R.M. Califf collaborates with scholars based in United States, New Zealand and Australia. R.M. Califf's co-authors include Eric J. Topol, Stephen G. Ellis, James E. Tcheng, Barry S. George, Harlan F. Weisman, Seth J. Worley, Russell J. Ivanhoe, Dan J. Fintel, M.J. Weston and Neal S. Kleiman and has published in prestigious journals such as The Lancet, Circulation and Annals of Internal Medicine.

In The Last Decade

R.M. Califf

26 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

1994 636 citations Eric J. Topol, R.M. Califf et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
R.M. Califf United States	14	1.3k	882	272	253	236	27	1.7k
Michael Ezekowitz United States	16	1.5k 1.1×	461 0.5×	313 1.2×	236 0.9×	85 0.4×	30	1.8k
Filippo Ottani Italy	23	1.7k 1.3×	617 0.7×	160 0.6×	810 3.2×	156 0.7×	76	2.2k
David Massel Canada	21	1.4k 1.1×	786 0.9×	490 1.8×	154 0.6×	411 1.7×	56	2.1k
Charles W. Abbottsmith United States	22	2.3k 1.8×	1.4k 1.6×	471 1.7×	883 3.5×	252 1.1×	34	2.7k
W.R.M. Aengevaeren Netherlands	22	736 0.6×	842 1.0×	72 0.3×	359 1.4×	74 0.3×	58	1.6k
Volker Schächinger Germany	20	1.3k 1.0×	669 0.8×	55 0.2×	512 2.0×	83 0.4×	64	1.7k
Raymond D. Bahr United States	14	736 0.6×	331 0.4×	103 0.4×	299 1.2×	55 0.2×	37	932
Can Yücel Karabay Türkiye	21	906 0.7×	335 0.4×	121 0.4×	313 1.2×	25 0.1×	123	1.3k
Mitsuru Abe Japan	25	1.9k 1.5×	1.0k 1.2×	276 1.0×	718 2.8×	25 0.1×	110	2.8k
André Roussin Canada	19	513 0.4×	727 0.8×	850 3.1×	43 0.2×	84 0.4×	36	2.1k

Countries citing papers authored by R.M. Califf

Since Specialization

Citations

This map shows the geographic impact of R.M. Califf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R.M. Califf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R.M. Califf more than expected).

Fields of papers citing papers by R.M. Califf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R.M. Califf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R.M. Califf. The network helps show where R.M. Califf may publish in the future.

Co-authorship network of co-authors of R.M. Califf

This figure shows the co-authorship network connecting the top 25 collaborators of R.M. Califf. A scholar is included among the top collaborators of R.M. Califf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R.M. Califf. R.M. Califf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shen, Long, Eric Reyes, Laine Thomas, et al.. (2013). Role of diuretics, blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. BMJ. 347(dec09 7). f6745–f6745. 87 indexed citations

Moukarbel, George V., James Signorovitch, Michael Pfeffer, et al.. (2009). Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. European Heart Journal. 30(18). 2226–2232. 77 indexed citations

Lópes, Renato D., Gretchen Marcucci, H. D. White, et al.. (2008). Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial. European Heart Journal. 29(15). 1827–1833. 34 indexed citations

Lincoff, A. Michael, R.M. Califf, & Frans Van de Werf. (2003). Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs. conventional fibrinolytic therapy for acute myocardial infarction. GUSTO V randomized trial. ACC Current Journal Review. 12(1). 18–18. 3 indexed citations

Campbell, Kevin R., et al.. (2000). Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention.. PubMed. 12 Suppl F. 14F–9. 60 indexed citations

Ohman, E. Magnus, Jonathan S. Schildcrout, Richard W. Smalling, et al.. (1998). Survival benefit of Abciximab administration during early rescue angioplasty: analysis of 387 patients from the GUSTO-III trial. Journal of the American College of Cardiology. 31. 191–191. 11 indexed citations

Anderson, R. David, HD White, E. Magnus Ohman, et al.. (1998). Resolution of ST-segment elevation 90 minutes after thrombolysis for acute myocardial infarction predicts outcome: a GUSTO-III substudy. Journal of the American College of Cardiology. 31. 371–371. 6 indexed citations

Harrington, RA, Carmelo Graffagnino, Mark J. Alberts, et al.. (1998). Comparison of stroke rates in patients with acute coronary syndromes and patients with acute myocardial infarction. Journal of the American College of Cardiology. 31. 406–406.

Wall, A. J., et al.. (1998). Failure to achieve optimal anticoagulation with commonly used heparin regimens; a review of GUSTO II. Journal of the American College of Cardiology. 31. 79–79. 6 indexed citations

10.

McClure, Matthew W., Lisa G. Berdan, Rodney Sparapani, et al.. (1998). Thrombocytopenia in a large, international trial of the GP IIb/IIIa inhibitor eptitibatide in patients with acute coronary syndromes. Journal of the American College of Cardiology. 31. 93–93. 5 indexed citations

11.

Granger, C. B., Paul W. Armstrong, John Simes, et al.. (1998). Hirudin reduces death and myocardial (RE)infarction at 6-months: follow-up results of the GUSTO IIb trial. Journal of the American College of Cardiology. 31. 79–79. 2 indexed citations

12.

Menon, Vandana, et al.. (1998). Lack of progress in cardiogenic shock: lessons from the GUSTO trials. Journal of the American College of Cardiology. 31. 136–136. 4 indexed citations

13.

Harrington, Richard, et al.. (1998). Clinical efficacy of integrilin in unstable angina is accompanied by a modest increase in hemorrhagic risk: the PURSUIT trial. Journal of the American College of Cardiology. 31. 185–185. 1 indexed citations

14.

Moliterno, David J., RA Harrington, Paul W. Armstrong, et al.. (1998). Late diverging event curves for survival following IIb/IIIa antagonism in patients with unstable angina: PARAGON study 1-year follow-up. Journal of the American College of Cardiology. 31. 208–209. 4 indexed citations

15.

Lauer, Michael S., et al.. (1998). Evidence for on adverse interaction between ACE inhibitors and aspirin following myocardial infarction: the GUSTO-I trial. Journal of the American College of Cardiology. 31. 96–96. 1 indexed citations

16.

Gilchrist, Ian C., Christopher B. Granger, Trevor Thompson, & R.M. Califf. (1998). Heparin dosing and outcome in acute coronary syndromes: the GUSTO-IIb experience. Journal of the American College of Cardiology. 31. 78–78. 1 indexed citations

17.

Califf, R.M., et al.. (1997). End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality. The Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I Angiographic Investigators. Circulation. 96(1). 116–121. 139 indexed citations

18.

Griffith, John L., Joni R. Beshansky, Christopher H. Schmid, et al.. (1997). Patient-Specific Predictions of Outcomes in Myocardial Infarction for Real-Time Emergency Use: A Thrombolytic Predictive Instrument. Annals of Internal Medicine. 127(7). 538–556. 67 indexed citations

19.

Topol, Eric J., R.M. Califf, Harlan F. Weisman, et al.. (1994). Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months. The Lancet. 343(8902). 881–886. 636 indexed citations breakdown →

20.

Williams, R. Sanders, Ray A. McKinnis, F R Cobb, et al.. (1984). Effects of physical conditioning on left ventricular ejection fraction in patients with coronary artery disease.. Circulation. 70(1). 69–75. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact